Premium
Platelet‐activating factor acetylhydrolase activity in red blood cell‐stroma from patients with cerebral thrombosis
Author(s) -
Yoshida H.,
Satoh K.,
Imaizumi T.,
Takamatsu S.,
Hiramoto M.,
Shoji B.,
Takamatsu M.
Publication year - 1992
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1992.tb05066.x
Subject(s) - platelet activating factor , red blood cell , phospholipid , platelet , medicine , endocrinology , thrombosis , red cell , chemistry , biochemistry , membrane
Platelet‐activating factor (1‐ O ‐alkyl‐2‐acetyl‐ sn ‐glycero‐3‐phosphocholine, PAF) is a bioactive phospholipid and inactivated by a specific enzyme, PAF acetylhydrolase (PAF‐AH). We have measured PAF‐AH activity in red blood cells (RBCs) from patients with a history of cerebral thrombosis and age‐matched healthy controls. The activities in 34 patients and 34 controls were 1.29 ± 0.28 and 1.64 ± 0.26 nmol/10 9 RBCs/min (or, 30.0 ± 5.8 and 35.1 ± 4.7 nmol/g protein/min) (mean ± SD), respectively, and the difference was significant ( p < 0.001). In patients, RBC PAF‐AH activity correlated positively with RBC filterability, an index of RBC deformability ( r = +0.501, p < 0.05). The RBC activity may play a role in scavenging oxidation products of membrane phospholipids. Lower RBC PAF‐AH activity may predispose to ischemic diseases by disturbing microcirculatory behavior of the RBCs.